The patients of the TCGA-PAAD cohort were divided into two groups based on the same percentage as in our cohort, (High SEMA3C mRNA (98/175: 56%) and Low SEMA3C mRNA (77/175: 44%)). This evidence concerns the gene SEMA3C and pancreatic adenocarcinoma.